The highest PTGDR2 expression in Q2 corresponded with a polysensitized allergic rhinitis patient (43.2-fold), and two asthmatic patients with CRSwNP and sensitivity to NSAIDs (AERD) (36.7- and 19.7-fold, respectively) (Figure 3). Here, PTGDR2 is linked to chronic rhinosinusitis with nasal polyps.